Nov 20, 2012 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. SWISSCOM AG ADS (NYSE:SCM), Celsion Corp (NASDAQ:CLSN), FALCON OIL & GAS LTD (OTC:FOLGF), Opexa Therapeutics Inc (NASDAQ:OPXA), Rosetta Genomics Ltd (NASDAQ:ROSG). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
SWISSCOM AG ADS (NYSE:SCM) - Swisscom AG is (Swisscom) is the principal provider of telecommunication services in Switzerland, offering a range of services to residential and business customers. As a provider of fixed-line services, the Company offers analog and digital access services. In addition, it offers broadband services over existing subscriber lines using a technology commonly referred to as asymmetric digital subscriber (ADSL). As of December 31, 2005, Swisscom provided 3.8 million fixed-line telephone access lines in Switzerland, of which 0.9 million were digital or integrated services digital network (ISDN) lines and 1.1 million were being used for line ADSL access. Through Swisscom Mobile AG, the Company is the mobile telecommunications service provider in Switzerland, with over 4.3 million subscribers to its mobile service as of December 31, 2005. Swisscom also offers a range of data services, from leased lines to integrated solutions for its business customers. During the year the Company operated in four segments: Fixnet, Mobile, Solutions and Other. The Solutions business segment was formed on January 1, 2005, when Swisscom Enterprise Solutions was merged with Swisscom Systems, to form a new business segment named Swisscom Solutions. On July 1, 2005, the Company acquired a 99% stake in Medipa AG, a Swiss medical billing company.
Through Fixnet, Swisscom is the provider of fixed network telecommunication services in Switzerland, which it provides to residential, business and wholesale customers. Fixnet accounted for 44% of the Company's consolidated net revenue during the year ended December 31, 2005. Services provided by Fixnet include: access, retail traffic, wholesale traffic, other traffic and other. Fixnet provides access services, including traditional analog, digital and broadband access services, to residential and business customers. As of December 31, 2005, Fixnet provided 3.8 million fixed-line telephone access lines, including 0.9 million ISDN lines, and offered ADSL access to approximately 1.1 million subscriber lines. Fixnet provides national and international fixed-line voice telephony services to residential and business customers. In 2005, Fixnet carried an aggregate of 9.8 billion minutes of national telephony and dial-up Internet traffic and 0.9 billion minutes of outgoing international traffic generated by residential customers.
Fixnet provides a range of wholesale services to Swisscom's other segments and to other telecommunications providers. In 2005, Fixnet billed a total of 15.9 billion minutes of national interconnection and transit traffic, carried 0.8 billion minutes of outgoing international traffic and terminated 1.6 billion minutes of incoming international traffic. Fixnet operates public payphones, provides operator services and offers prepaid calling cards. Fixnet also offers a variety of other services, including the sale of customer equipment, the provision of leased lines and the operation of a directories database.
The Company competes with Cablecom and TDC (Sunrise), Tele2, colt and Solaris.
Swisscom Mobile is the provider of mobile telephony services in Switzerland, with 4.3 million mobile subscribers as of December 31, 2005. In 2005, Swisscom Mobile accounted for 38% of the Company's consolidated net revenue. The Company offers its customers mobile telephony service in Switzerland, as well as abroad. The Company has roaming agreements with 425 mobile network operators worldwide covering 179 countries and earns revenue from those operators when their subscribers make mobile phone calls in Switzerland.
Swisscom offers a variety of mobile products, including pre- and post-paid products and products where calls are charged on either per minute or per call basis. All of the Company's mobile products except its data-only and prepaid, provides its customers with the range of mobile services, allowing them to make and receive calls within Switzerland or internationally, using the same telephone number over Global System for Mobile Communications (GSM) and/or Universal. There is a failure to deliver in shares of SCM
Celsion Corp (NASDAQ:CLSN) - Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company is developing its lead product, ThermoDox that is in Phase III clinical trial for primary liver cancer; and in phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a license agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market. The company also has a license agreement with Duke University under which it received exclusive rights to commercialize and use Duke's thermo-liposome technology. In addition, Celsion Corporation has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat a range of cancers. The company was founded in 1982 and is based in Columbia, Maryland.. There is a failure to deliver in shares of CLSN
FALCON OIL & GAS LTD (OTC:FOLGF) - Falcon Oil & Gas Ltd., a development stage company, engages in the acquisition, exploration, and development of petroleum and natural gas properties in Canada, Hungary, Romania, Australia, and the United States. The company holds two petroleum and natural gas exploration licenses, the Tisza License and the Mako License located in south central Hungary; 75% working interest in 4 exploration permits in the Northern Territory, Australia; and working interests in four producing petroleum and natural gas wells in Alberta, Canada. It also owns a 25% non-operating working interest in 5 wells in the Buckskin Mesa area situated in the Piceance Basin, Colorado. The company was incorporated in 1980 and is headquartered in Denver, Colorado with additional offices in Vancouver, Canada; Budapest, Hungary; and Darwin and Sydney, Australia.. There is a failure to deliver in shares of FOLGF
Opexa Therapeutics Inc (NASDAQ:OPXA) - Opexa Therapeutics, Inc., a biopharmaceutical company, develops patient-specific cellular therapies for the treatment of autoimmune diseases. Its lead product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine under Phase IIb clinical trial for the treatment of multiple sclerosis. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.. There is a failure to deliver in shares of OPXA
Rosetta Genomics Ltd (NASDAQ:ROSG) - Rosetta Genomics Ltd. develops microRNA-based diagnostic and in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in deoxyribonucleic acid and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of body fluid-based diagnostic tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the companys microRNA-based cancer diagnostic tests; and a collaboration agreement with CBR Institute for Biomedical Research to study the role of microRNAs in hematopoeisis. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.. There is a failure to deliver in shares of ROSG
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Thomas Ronk / CEO
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to firstname.lastname@example.org.